National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 494024

(NOTE: This result is from the 9/17/2013 version of the VAERS database)

Case Details

VAERS ID: 494024 (history)  
Form: Version .0  
Age: 18.0  
Sex: Male  
Location: Texas  
Vaccinated:2012-01-25
Onset:2012-01-25
   Days after vaccination:0
Submitted: 2013-06-12
   Days after onset:503
Entered: 2013-06-12
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. 1397AA / 0 LA / IM
MNQ: MENINGOCOCCAL CONJUGATE (MENACTRA) / SANOFI PASTEUR U4032AA / 1 LA / IM

Administered by: Public       Purchased by: Public
Symptoms: Acute myeloid leukaemia, Aspartate aminotransferase increased, Band neutrophil percentage increased, Bilirubin conjugated increased, Blast cell count increased, Blood albumin decreased, Blood bilirubin increased, Blood chloride increased, Blood creatinine increased, Blood fibrinogen decreased, Blood gases abnormal, Blood glucose increased, Blood lactate dehydrogenase increased, Blood magnesium increased, Blood smear test abnormal, Blood sodium increased, Blood urea increased, Breath sounds abnormal, Cardiac arrest, Central venous catheterisation, Cerebral haemorrhage, Chest X-ray abnormal, Coma, Computerised tomogram head abnormal, Contusion, Corneal reflex decreased, Death, Depressed level of consciousness, Disseminated intravascular coagulation, Ecchymosis, Endotracheal intubation, Fluorescent in situ hybridisation, Glomerular filtration rate decreased, HIV test negative, Haematemesis, Haematocrit decreased, Haemoglobin decreased, Haptoglobin increased, Hypertonia, Injection site bruising, Intensive care, International normalised ratio increased, Legionella test, Leukaemia, Lymphocyte percentage decreased, Malaise, Mean cell haemoglobin concentration increased, Mean platelet volume increased, Mechanical ventilation, Mental status changes, Metamyelocyte percentage increased, Mucosal dryness, Mydriasis, Myelocyte percentage increased, Nausea, Neutrophil percentage decreased, Oedema peripheral, Oropharyngeal pain, Pallor, Petechiae, Platelet count decreased, Platelet transfusion, Posturing, Promyelocyte count increased, Protein total decreased, Prothrombin time prolonged, Purpura, Pyrexia, Red blood cell count decreased, Red cell distribution width increased, Renal failure acute, Respiratory failure, Resuscitation, Sepsis, Staphylococcus test negative, Thrombocytopenia, Transfusion, Unresponsive to stimuli, Upper respiratory tract infection, White blood cell count increased
SMQs:, Torsade de pointes/QT prolongation (broad), Rhabdomyolysis/myopathy (broad), Acute renal failure (narrow), Cardiac failure (broad), Liver related investigations, signs and symptoms (narrow), Liver-related coagulation and bleeding disturbances (narrow), Anaphylactic reaction (narrow), Acute pancreatitis (narrow), Agranulocytosis (broad), Angioedema (broad), Haematopoietic erythropenia (narrow), Haematopoietic leukopenia (broad), Haematopoietic thrombocytopenia (narrow), Lactic acidosis (broad), Haemorrhage terms (excl laboratory terms) (narrow), Haemorrhage laboratory terms (broad), Hyperglycaemia/new onset diabetes mellitus (narrow), Neuroleptic malignant syndrome (narrow), Systemic lupus erythematosus (broad), Anticholinergic syndrome (broad), Arrhythmia related investigations, signs and symptoms (broad), Haemorrhagic cerebrovascular conditions (narrow), Retroperitoneal fibrosis (broad), Shock-associated circulatory or cardiac conditions (excl torsade de pointes) (narrow), Torsade de pointes, shock-associated conditions (broad), Hypovolaemic shock conditions (broad), Toxic-septic shock conditions (broad), Anaphylactic/anaphylactoid shock conditions (broad), Hypoglycaemic and neurogenic shock conditions (broad), Dementia (broad), Embolic and thrombotic events, vessel type unspecified and mixed arterial and venous (narrow), Embolic and thrombotic events, venous (narrow), Blood premalignant disorders (narrow), Dystonia (broad), Parkinson-like events (narrow), Gastrointestinal haemorrhage (narrow), Oropharyngeal conditions (excl neoplasms, infections and allergies) (narrow), Acute central respiratory depression (narrow), Psychosis and psychotic disorders (narrow), Biliary system related investigations, signs and symptoms (narrow), Guillain-Barre syndrome (broad), Noninfectious encephalitis (broad), Noninfectious encephalopathy/delirium (broad), Noninfectious meningitis (broad), Accidents and injuries (narrow), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Haemodynamic oedema, effusions and fluid overload (narrow), Cardiomyopathy (broad), Corneal disorders (narrow), Malignant tumours (narrow), Hypotonic-hyporesponsive episode (broad), Generalised convulsive seizures following immunisation (broad), Chronic kidney disease (broad), Hypersensitivity (broad), Myelodysplastic syndrome (broad), Tumour lysis syndrome (broad)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2012-02-10
   Days after onset: 16
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 3 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications: None known
Current Illness: None known
Preexisting Conditions: None known The following information was obtained through follow-up and/or provided by the government. PMH: back strain Dec 2011. Occasional marijuana use.
Allergies:
Diagnostic Lab Data: The following information was obtained through follow-up and/or provided by the government. 6/17 & 27/2013 lab/diagnostic records received for DOS 2/7-10/2012. Blood: WBC 41.9 K/uL (H), segs 5% (L), bands 3% (H), lymphs 14% (L), metamyelocytes 13% (H), myelocyte 13% (H), promyelocyte 14% (H), blast 41% (H), Plt 12 K/uL (L), MPV 10.8 K/uL (H), RBC 2.63 M/uL (L), Hgb 7.7 g/dL (L), Hct 22.6% (L), MCHC 36.2 g/dL (H), RDW 15.4% (H), Na 159 mmol/L (H), Cl 118 mmol/L (H), Mg 2.4 mg/dL (H), glucose 255 mg/dL (H), BUN 42 mg/dL (H), creatinine 3.8 mg/dL (H), GFR 22 (L), protein 6.3 g/dL (L), albumin 2.6 g/dL (L), PT 18.8 sec (H), INR 1.63 (H), fibrinogen 165 mg/dL (L), bili total 2.6 mg/dL (H), direct bili 0.33 mg/dL (H), AST 130 U/L (H), LDH 851 U
CDC Split Type:

Write-up: On 1/25/2012, as per mother patient developed a black bruise to the left upper arm where vaccines had been administered that covered most of the entire upper arm. On February 1, 2012, he developed a sore throat and fever that lasted a week. On February 7, 2012 at 11 am he reported to hospital. As per mother, patient was non-responsive and was throwing up blood-tinged saliva. He was flown out due to an internal hemorrhage. He was admitted to hospital at around 3 pm. After admission, he remained unresponsive. As per mother, the internal cerebral hemorrhage was too advanced and the patient was not a candidate for surgery so patient eventually became comatose. He passed away on 2/10/2012 at 2 am. Final diagnosis was cerebral hemorrhage and leukemia. As per parent, the client had no previous history of illnesses at the time of vaccination on 1/25/2012. The following information was obtained through follow-up and/or provided by the government. 6/17/2013 hospital records received for DOS 2/7-10/2012. D/c Dx''s: 1) acute myeloblastic leukemia; 2) intracerebral hemorrhage; 3) cerebral coma; 4) acute kidney injury. Pt to outside facility w/ 2 wk hx URI & easy bruising. Progressed to sore throat, fever, feeling unwell, nausea, vomiting, then altered mentation. Intubated for suspected acute respiratory failure thought to be 2^ to meningococemia. Pt transferred in critical condition w/ severe thrombocytopenia, petechia, purpura, sepsis, DIC. Arrival PE: intubated, central line, obtunded, occasional extensor posturing, hypertonicity, LE edema, pupils dilated, poor corneal reflexes, unresponsive to painful stimuli, pallor, dry oropharygeal mucosa, vesicular breath sounds in all regions, ecchymotic areas to LE & abdomen. Admitted to ICU. Tx''t: mannitol, hyperventilation, Plt & RBC transfusions. Evidence of acute myeloblastic leukemia, large intracerebral hemorrhage 2^ to severe thrombocytopenia, minimal brainstem function. Developed cardiac arrest, unable to resuscitate, pronounced dead.


New Search

Link To This Search Result:

https://www.medalerts.org/vaersdb/findfield.php?SNAPSHOT=20130917&IDNUMBER=494024


Copyright © 2020 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166